GlassScriptPhysician profile
Erene Sami
NPI 1023335817
$3,655.23
in general payments reported to CMS, 2019-2025
34 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $235 · 2021: $950 · 2022: $262 · 2023: $216 · 2024: $483 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046 · Travel and Lodging: $8.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.05 |
| Travel and Lodging | $8.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $777.91 | 2019-2024 | Ozempic |
| Lilly USA, LLC | $549.27 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.91 | 2019-2025 | Jardiance |
| Amgen INC. | $254.95 | 2019-2025 | Repatha, Repatha |
| Dexcom, INC. | $210.55 | 2019-2024 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $155.13 | 2024 | Isturisa |
| Corcept Therapeutics | $153.12 | 2021-2025 | Korlym |
| Abbvie INC. | $143.06 | 2019-2021 | |
| Abbott Laboratories | $110.66 | 2020-2025 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $105.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $98.11 | 2020-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $89.63 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.97 | 2021-2024 | |
| Lifescan, INC. | $58.67 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $54.40 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $52.66 | 2020-2024 | |
| Radius Health, INC. | $49.09 | 2019-2024 | Tymlos |
| Alexion Pharmaceuticals, INC. | $48.58 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $48.41 | 2019 | |
| Horizon Therapeutics Plc | $47.02 | 2020-2021 | |
| Madrigal Pharmaceuticals | $33.19 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $28.23 | 2025 | |
| Ibsa Pharma INC. | $26.52 | 2021 | |
| Akebia Therapeutics INC | $25.85 | 2025 | Vafseo |
| Aimmune Therapeutics, INC. | $24.48 | 2025 | Zenpep |
| Medtronic, INC. | $24.24 | 2024 | Minimed 780g |
| Valeritas, INC. | $23.59 | 2019 | |
| Bigfoot Biomedical INC | $21.45 | 2022 | |
| Zealand Pharma US, INC. | $21.28 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.76 | 2021 | |
| Intra-Sana Laboratories | $17.31 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Merck Sharp & Dohme LLC | $14.54 | 2019 | |
| Tandem Diabetes Care, INC. | $12.87 | 2022 | |
| Amarin Pharma, INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erene Sami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.